Adaptimmune Therapeutics PLC — Director's Dealing 2018

Jul 6, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2018-07-05

Reporting Person: Furey John (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$1.96	2028-07-05	Ordinary Shares (284233)		Direct

Footnotes

F1: Exercisable as to 71,058 Ordinary Shares on July 5, 2019 and will be exercisable as to the remainder in monthly installments of 8,882 Ordinary Shares on the fifth of each month from August 5, 2019 through June 5, 2021, and in one installment of 8,889 Ordinary Shares on July 5, 2021.

F2: The exercise price was converted from GBP1.49 based on an exchange rate of $U.S. 1.3176 to GBP1.00. The actual exercise price will be the pounds sterling amount.